Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )
Study sponsor: Revolution Medicines, Inc. · RVMD
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2028-12-30Estimated
Enrollment · participants670Estimated
Source updated2026-11-06Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.